The development of highly efficient catalysts for room-temperature formaldehyde (HCHO) oxidation is of great interest for indoor air purification. In this work, it was found that the single-atom Pt 1 /CeO 2 catalyst exhibits a remarkable activity with complete removal of HCHO even at 288 K. Combining density functional theory calculations and in situ DRIFTS experiments, it was revealed that the active O lattice H site generated on CeO 2 in the vicinity of Pt 2+ via steam treatment plays a key role in the oxidation of HCHO to formate and its further oxidation to CO 2 . Such involvement of hydroxyls is fundamentally different from that of cofeeding water which dissociates on metal oxide and catalyzes the acid–base-related chemistry. This study provides an important implication for the design and synthesis of supported Pt catalysts with atom efficiency for a very important practical application—room-temperature HCHO oxidation.

Background Fistulas have puzzled us all the time and stem cell therapy for it is still in its infancy. We conducted a meta-analysis and systematic review to evaluate the efficacy of stem cells and its potential mechanisms in the management of Crohn’s fistula. Methods Electronic databases were searched comprehensively for studies reporting the efficacy and safety of stem cells in patients with any form of Crohn’s fistula. A random-effects model was used, and all outcomes were calculated by SPSS 24.0. Results Twenty-nine articles with 1252 patients were included. It showed that stem cell group had a higher rate of fistula healing compared to placebo group in patients of Crohn’s fistula (61.75% vs 40.46%, OR 2.21, 95% CI 1.19 to 4.11, P < 0.05). 3 × 107 cells/mL stem cell (SC) group had an advantage in fistula healing rate with 71.0% compared to other doses group of stem cells (RR 1.3, 95% CI 0.76 to 2.22). And the healing rates of patients with perianal and transsphincteric fistulas (77.95%, 76.41%) were higher than those with rectovaginal fistulas. It was an amazing phenomenon that CDAI and PDAI scores occurred an obviously transient rise with the use of stem cells after 1 month (both of P < 0.05), while they returned to the baseline level by giving stem cells 3 months later. Furthermore, the incidence rate of treatment-related adverse events in the stem cell group was significantly lower than in the placebo group (RR 0.58, 95% CI 0.30 to 1.14). Conclusions Our study has highlighted that stem cells was a promising method in the treatment of Crohn’s fistula based on its higher efficacy and lower incidence of adverse events, especially ADSCs and Cx601. While it also needs more clinical and pre-clinical studies to strengthen evidences in the future.

Background and Aims Fecal microbiota transplantation (FMT) has challenged the traditional management of ulcerative colitis (UC) in recent years, while it remained controversial. We aimed to provide a systematic protocol of FMT treatment on UC. Methods Studies reporting on FMT treatment in UC patients were performed. A fixed-effect model was used to assess the efficacy of FMT. Results Eighteen studies were enrolled (n = 446). A pooled proportion of patients who received FMT had a significant efficacy compared to the placebo group (odds ratio (OR): 2.73, P = 0.002) with a low risk of heterogeneity (P = 0.59, I2 = 0%). The Mayo score decreased to 5 points in a state of mild–moderate activity after FMT treatment, and the optimal range of the Mayo score baseline was 6–9 for FMT administration. Then, the baseline of the Shannon diversity index (SDI) had a negative correlation with the clinical response rate (R = −0.992, P = 0.08) or remission rate (R = −0.998, P = 0.036), and the optimal diversity of bacteria was at 7 days to one month. Moreover, the colonoscopy delivery and unrelated fecal donor had slight superiorities of FMT treatment. Conclusion FMT treatment had a higher efficacy and shorter time-point of early assessment of effectiveness on UC patients compared to traditional therapies. And the optimal FMT delivery and donor were colonoscopy delivery and unrelated donor in clinical practice.

A Pd/Al2O3 nanocatalyst was pretreated at 750 °C in air, Ar or H2O/Ar, respectively. The effect of these different pretreatments on the active species and reactivity of Pd/Al2O3 in formaldehyde oxidation at room temperature was investigated. The pretreatment was found to affect both the phase transformation of PdO to Pd metal and the Pd dispersion, leading to different catalytic performances. We found that the Pd/Al2O3 nanocatalyst pretreated in both Ar and H2O/Ar show 60 % and 100 % formaldehyde conversion at 25 °C, respectively, while the catalyst pretreated in air is not active under the same condition. Pretreatments in both Ar and H2O/Ar were found to facilitate the formation of metallic Pd on Pd/Al2O3 catalyst, confirmed by both experiments and calculation based on the function of the equilibrium oxygen pressure and temperature. We further found that the catalyst pretreated in H2O/Ar has higher Pd dispersion and more surface OH groups compared to that pretreated in Ar, leading to improved activity in formaldehyde oxidation.

No abstract

No abstract

Background and Aims Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods Clinical researches reporting MSCT in LF patients were searched and included. Results Nine articles (n = 476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month (P < 0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 μmol/L at 2 and 3 months (P < 0.05). Notably, the decreased value (D value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, P < 0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT (P = 0.003). Conclusion The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the D value of MELD.

No abstract